Introduction: In patients with a history of malignancy, follow-up surveillance of lymph nodes (LNs) is required to evaluate for potential malignancy or infection. In some cases, the lymphadenopathy may be secondary to an intraprocedural hemostatic agent and/or related granulomatous reaction. Case Presentation: We present the case of an 80-year-old female with a remote past medical history of breast cancer status post-lumpectomy and chemoradiation. Twenty years later, a 2.4 cm pulmonary right middle lobe nodule was noted on imaging studies. She underwent bronchoscopy, cervical mediastinoscopy, and right middle lobe wedge resection. The final pathologic diagnosis was a pulmonary carcinoid tumor, and the excised mediastinal LN was negative for malignancy. A 10-month surveillance positron emission tomography scan showed new mildly avid mediastinal and right hilar LNs. The following endobronchial ultrasound-guided transbronchial needle aspiration showed unremarkable lymphoid elements in the enlarged 4R LN, while the station 7 LN demonstrated ample dense hyaline-like foreign material. Subsequent review of the cell block/biopsy and communication with the thoracic surgeon revealed that Surgicel® (or oxidized regenerated cellulose) was placed during surgery at the station 7 site. Discussion/Conclusion: Assessment of the findings and based on the similar histologic appearance reported in previous cases associated with Surgicel® [Ann Thorac Med. 2017;12(1):55–6, Cancer Cytopathol. 2019;127(12):765–70, and Arch Bronconeumol. 2020;56(7):459–71], the station 7 acellular, amorphous, and hyaline-like exogenous material found in our case was interpreted as hemostatic agent compatible with Surgicel® (or oxidized regenerated cellulose). This case highlights the importance of cytologic/histologic recognition of hemostatic agents, specifically oxidized cellulose mesh.

1.
Badenes
D
,
Pijuan
L
,
Curull
V
,
Sanchez-Font
A
.
A foreign body reaction to Surgicel® in a lymph node diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration
.
Ann Thorac Med
.
2017
;
12
(
1
):
55
6
. .
2.
Ibrahim
MF
,
Aps
C
,
Young
CP
.
A foreign body reaction to Surgicel mimicking an abscess following cardiac surgery
.
Eur J Cardiothorac Surg
.
2002
;
22
(
3
):
489
90
; author reply 490. .
3.
Oto
A
,
Remer
EM
,
O’Malley
CM
,
Tkach
JA
,
Gill
IS
.
MR characteristics of oxidized cellulose (Surgicel)
.
AJR Am J Roentgenol
.
1999
;
172
(
6
):
1481
4
. .
4.
Sugar
O
.
Editorial: oxidized cellulose hemostat (Surgicel)
.
Surg Neurol
.
1984
;
21
(
5
):
521
. .
5.
Menovsky
T
,
Plazier
M
,
Rasschaert
R
,
Maas
A
,
Parizel
P
,
Verbeke
S
.
Massive swelling of Surgicel® Fibrillar™ hemostat after spinal surgery. Case report and a review of the literature
.
Minim Invasive Neurosurg
.
2011
;
54
(
5–6
):
257
9
. .
6.
Sabel
M
,
Stummer
W
.
Haemostasis in spine surgery. The use of local agents: Surgicel and Surgifoam
.
Eur Spine J
.
2004
;
13
(
Suppl 1
):
S97
101
. .
7.
Martinez
A
,
Pubul
V
,
Jokh
EA
,
Martinez
A
,
El-Diasty
M
,
Fernandez
AL
.
Surgicel-related uptake on positron emission tomography scan mimicking prosthetic valve endocarditis
.
Ann Thorac Surg
.
2021
;
112
(
5
):
e317
9
. .
8.
Hernandez-Bonilla
S
,
Rodriguez-Garcia
AM
,
Jimenez-Heffernan
JA
,
Munoz-Hernandez
P
,
Palacios-Lazaro
E
,
Lopez-Ferrer
P
,
FNA cytology of postoperative pseudotumoral lesions induced by oxidized cellulose hemostatic agents
.
Cancer Cytopathol
.
2019
;
127
(
12
):
765
70
. .
9.
Díaz Lopez
JM
,
Caballero Vázquez
A
,
López Hidalgo
JL
,
Márquez Lobo
B
.
EBUS-TBNA diagnosis of a granulomatous reaction to Surgicel® in mediastinal adenopathy
.
Arch Bronconeumol
.
2020
;
56
(
7
):
459
71
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.